C. Warren Olanow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
C. Warren Olanow has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Fabrizio Stocchi
Department of Neurology, University San Raffaele, Rome, Italy
9 shared publications Karl Kieburtz
University of Rochester Medical Center, Rochester, NY, USA
7 shared publicationsJoseph Jankovic
Department of Neurology, Baylor University, Houston, TX, USA
5 shared publications- Anthony E. Lang
Division of Neurology, Department of Medicine University of Toronto Toronto ON Canada
4 shared publications Jeffrey H. Kordower
Rush University Medical Center, Chicago, Illinois, USA
4 shared publicationsOlivier Rascol
INSERM U455, Clinical Investigation Center, Faculty of Medicine, Toulouse, France
4 shared publications
Latest Publications
- 1 December 2017
- Published by Elsevier in Experimental Neurology
- Vol. 298, 246-251
Clinical approaches to the development of a neuroprotective therapy for PD
- 1 December 2017
- Published by Elsevier in Experimental Neurology
- Vol. 298, 246-251
Clinical approaches to the development of a neuroprotective therapy for PD
- 14 November 2015
- Published by Wiley in Movement Disorders
- Vol. 30 (13) , 1715-1724
Trophic factors for Parkinson's disease: To live or let die
Trophic factors show great promise in laboratory studies as potential therapies for PD. However, multiple double‐blind, clinical trials have failed to show benefits in comparison to a placebo control. This article will review the scientific rationale for testing trophic factors in PD, the results of the different clinical trials that have been performed to date, and the possible explanations for these failed outcomes. We will also consider future directions and the likelihood that trophic factors will become a viable therapy for patients with PD. © 2015 International Parkinson and Movement Disorder Society
- 14 November 2015
- Published by Wiley in Movement Disorders
- Vol. 30 (13) , 1715-1724
Trophic factors for Parkinson's disease: To live or let die
Trophic factors show great promise in laboratory studies as potential therapies for PD. However, multiple double‐blind, clinical trials have failed to show benefits in comparison to a placebo control. This article will review the scientific rationale for testing trophic factors in PD, the results of the different clinical trials that have been performed to date, and the possible explanations for these failed outcomes. We will also consider future directions and the likelihood that trophic factors will become a viable therapy for patients with PD. © 2015 International Parkinson and Movement Disorder Society
- 11 December 2014
- Published by Wiley in Movement Disorders
- Vol. 30 (1) , 37-44
Levodopa: Effect on cell death and the natural history of Parkinson's disease
This review article considers the question of whether or not levodopa is toxic in Parkinson's disease (PD).l‐dopa is the most effective symptomatic treatment for PD and has provided benefit for millions of patients. However, there has been a longstanding concern thatl‐dopa might be toxic and accelerate neuronal degeneration and clinical progression as a consequence of reactive oxygen species generated by the drug's oxidative metabolism. In vitro,l‐dopa can induce degeneration of dopaminergic neurons, but it is not clear that the effects of the drug on cultured dopamine neurons reflect what happens in the PD brain. In vivo,l‐dopa has not been demonstrated to have toxic effects on dopamine neurons in normal, dopamine‐lesioned, or oxidatively stressed animal models, but none of these models precisely replicates the PD condition. Clinical trials have tested the effect ofl‐dopa on clinical progression and have not demonstrated any findings indicative of toxicity. However, the symptomatic and long‐duration effects of the drug could mask ongoing neuronal degeneration. Furthermore,l‐dopa induces a greater decline in imaging measures of dopaminergic function than placebo or dopamine agonists, consistent with toxicity. Pathological studies have not demonstrated evidence of accelerated loss of dopamine neurons, but prospective and properly controlled studies with stereological unbiased counting have not been performed. Thus, although there is no hard evidence to suggest thatl‐dopa is toxic in PD patients, the issue has not been fully resolved. It is generally recommended that physicians continue to usel‐dopa, but in the lowest dose that provides satisfactory clinical control. © 2014 International Parkinson and Movement Disorder Society
- 11 December 2014
- Published by Wiley in Movement Disorders
- Vol. 30 (1) , 37-44
Levodopa: Effect on cell death and the natural history of Parkinson's disease
This review article considers the question of whether or not levodopa is toxic in Parkinson's disease (PD).l‐dopa is the most effective symptomatic treatment for PD and has provided benefit for millions of patients. However, there has been a longstanding concern thatl‐dopa might be toxic and accelerate neuronal degeneration and clinical progression as a consequence of reactive oxygen species generated by the drug's oxidative metabolism. In vitro,l‐dopa can induce degeneration of dopaminergic neurons, but it is not clear that the effects of the drug on cultured dopamine neurons reflect what happens in the PD brain. In vivo,l‐dopa has not been demonstrated to have toxic effects on dopamine neurons in normal, dopamine‐lesioned, or oxidatively stressed animal models, but none of these models precisely replicates the PD condition. Clinical trials have tested the effect ofl‐dopa on clinical progression and have not demonstrated any findings indicative of toxicity. However, the symptomatic and long‐duration effects of the drug could mask ongoing neuronal degeneration. Furthermore,l‐dopa induces a greater decline in imaging measures of dopaminergic function than placebo or dopamine agonists, consistent with toxicity. Pathological studies have not demonstrated evidence of accelerated loss of dopamine neurons, but prospective and properly controlled studies with stereological unbiased counting have not been performed. Thus, although there is no hard evidence to suggest thatl‐dopa is toxic in PD patients, the issue has not been fully resolved. It is generally recommended that physicians continue to usel‐dopa, but in the lowest dose that provides satisfactory clinical control. © 2014 International Parkinson and Movement Disorder Society
- Open Access
- 8 December 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (50) , 17693-17695
Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees
- 8 December 2014
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (50) , 17693-17695
Open AccessProfile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees
- Top Cited Papers
- 1 February 2014
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (2) , 141-149
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
- 1 February 2014
- Published by Elsevier in The Lancet Neurology
- Vol. 13 (2) , 141-149
Top Cited PapersContinuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
- 9 January 2014
- Published by Wiley in Movement Disorders
- Vol. 29 (3) , 430
Initiating levodopa therapy for Parkinson's disease
- 9 January 2014
- Published by Wiley in Movement Disorders
- Vol. 29 (3) , 430
Initiating levodopa therapy for Parkinson's disease
- 1 January 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (1) , 31-40
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Altered protein handling is thought to play a key role in the etiopathogenesis of Parkinson's disease (PD), as the disorder is characterized neuropathologically by the accumulation of intraneuronal protein aggregates (Lewy bodies and Lewy neurites). Attention has particularly focused on the α‐synuclein protein, as it is the principal component of Lewy pathology. Moreover, point mutations in the α‐synuclein gene cause rare familial forms of PD. Importantly, duplication/triplication of the wild type α‐synuclein gene also cause a form of PD, indicating that increased levels of the normal α‐synuclein protein is sufficient to cause the disease. Further, single nucleotide polymorphisms in the α‐synuclein gene are associated with an increased risk of developing sporadic PD. Recent evidence now suggests the possibility that α‐synuclein is a prion‐like protein and that PD is a prion‐like disease. Within cells, α‐synuclein normally adopts an α‐helical conformation. However, under certain circumstances, the protein can undergo a profound conformational transition to a β‐sheet–rich structure that polymerizes to form toxic oligomers and amyloid plaques. Recent autopsy studies of patients with advanced PD who received transplantation of fetal nigral mesencephalic cells more than a decade earlier demonstrated that typical Lewy pathology had developed within grafted neurons. This suggests that α‐synuclein in an aberrantly folded, β‐sheet–rich form had migrated from affected to unaffected neurons. Laboratory studies confirm that α‐synuclein can transfer from affected to unaffected nerve cells, where it appears that the misfolded protein can act as a template to promote misfolding of host α‐synuclein. This leads to the formation of larger aggregates, neuronal dysfunction, and neurodegeneration. Indeed, recent reports demonstrate that a single intracerebral inoculation of misfolded α‐synuclein can induce Lewy‐like pathology in cells that can spread from affected to unaffected regions and can induce neurodegeneration with motor disturbances in both transgenic and normal mice. Further, inoculates derived from the brains of elderly α‐synuclein–overexpressing transgenic mice have now been shown to accelerate the disease process when injected into the brains of young transgenic animals. Collectively, these findings support the hypothesis that α‐synuclein is a prion‐like protein that can adopt a self‐propagating conformation that causes neurodegeneration. We propose that this mechanism plays an important role in the development of PD and provides novel targets for candidate neuroprotective therapies. © 2013 Movement Disorder Society
- 1 January 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (1) , 31-40
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Altered protein handling is thought to play a key role in the etiopathogenesis of Parkinson's disease (PD), as the disorder is characterized neuropathologically by the accumulation of intraneuronal protein aggregates (Lewy bodies and Lewy neurites). Attention has particularly focused on the α‐synuclein protein, as it is the principal component of Lewy pathology. Moreover, point mutations in the α‐synuclein gene cause rare familial forms of PD. Importantly, duplication/triplication of the wild type α‐synuclein gene also cause a form of PD, indicating that increased levels of the normal α‐synuclein protein is sufficient to cause the disease. Further, single nucleotide polymorphisms in the α‐synuclein gene are associated with an increased risk of developing sporadic PD. Recent evidence now suggests the possibility that α‐synuclein is a prion‐like protein and that PD is a prion‐like disease. Within cells, α‐synuclein normally adopts an α‐helical conformation. However, under certain circumstances, the protein can undergo a profound conformational transition to a β‐sheet–rich structure that polymerizes to form toxic oligomers and amyloid plaques. Recent autopsy studies of patients with advanced PD who received transplantation of fetal nigral mesencephalic cells more than a decade earlier demonstrated that typical Lewy pathology had developed within grafted neurons. This suggests that α‐synuclein in an aberrantly folded, β‐sheet–rich form had migrated from affected to unaffected neurons. Laboratory studies confirm that α‐synuclein can transfer from affected to unaffected nerve cells, where it appears that the misfolded protein can act as a template to promote misfolding of host α‐synuclein. This leads to the formation of larger aggregates, neuronal dysfunction, and neurodegeneration. Indeed, recent reports demonstrate that a single intracerebral inoculation of misfolded α‐synuclein can induce Lewy‐like pathology in cells that can spread from affected to unaffected regions and can induce neurodegeneration with motor disturbances in both transgenic and normal mice. Further, inoculates derived from the brains of elderly α‐synuclein–overexpressing transgenic mice have now been shown to accelerate the disease process when injected into the brains of young transgenic animals. Collectively, these findings support the hypothesis that α‐synuclein is a prion‐like protein that can adopt a self‐propagating conformation that causes neurodegeneration. We propose that this mechanism plays an important role in the development of PD and provides novel targets for candidate neuroprotective therapies. © 2013 Movement Disorder Society
- 1 January 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (1) , 3-7
Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
A neuroprotective or disease‐modifying therapy that can slow or stop disease progression and prevent the development of intolerable disability is the major unmet medical need in the treatment of Parkinson's disease (PD). Many putative neuroprotective agents have been identified in the laboratory, but none has been unequivocally demonstrated to provide disease‐modifying effects in PD patients, even when clinical trials are positive. Obstacles to defining a neuroprotective therapy in PD include: (1) uncertainty about the cause of PD and precisely what to target, (2) a reliable animal model in which to test putative neuroprotective agents that accurately predicts results in PD patients, (3) insight about which dose to employ in clinical trials and which patient group to study, (4) a clinical trial design that reliably differentiates disease‐modifying and symptomatic effects and that is acceptable to regulatory authorities, and (5) the cost and time of the development program. Advances have been made in each of these areas, thereby increasing the prospects of developing a neuroprotective or disease‐modifying therapy in the not‐too‐distant future. These issues are reviewed in the present article. © 2013 Movement Disorder Society
- 1 January 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (1) , 3-7
Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
A neuroprotective or disease‐modifying therapy that can slow or stop disease progression and prevent the development of intolerable disability is the major unmet medical need in the treatment of Parkinson's disease (PD). Many putative neuroprotective agents have been identified in the laboratory, but none has been unequivocally demonstrated to provide disease‐modifying effects in PD patients, even when clinical trials are positive. Obstacles to defining a neuroprotective therapy in PD include: (1) uncertainty about the cause of PD and precisely what to target, (2) a reliable animal model in which to test putative neuroprotective agents that accurately predicts results in PD patients, (3) insight about which dose to employ in clinical trials and which patient group to study, (4) a clinical trial design that reliably differentiates disease‐modifying and symptomatic effects and that is acceptable to regulatory authorities, and (5) the cost and time of the development program. Advances have been made in each of these areas, thereby increasing the prospects of developing a neuroprotective or disease‐modifying therapy in the not‐too‐distant future. These issues are reviewed in the present article. © 2013 Movement Disorder Society
- 2 October 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (12) , 1475-1477
Stem cells for Parkinson's disease: Advancing science but protecting patients
- 2 October 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (12) , 1475-1477
Stem cells for Parkinson's disease: Advancing science but protecting patients
- Top Cited Papers
- 1 December 2010
- Published by Elsevier in The Lancet Neurology
- Vol. 9 (12) , 1164-1172
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- 1 December 2010
- Published by Elsevier in The Lancet Neurology
- Vol. 9 (12) , 1164-1172
Top Cited PapersGene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial